Monitoring cognitive impairment through speech with Cambridge Cognition

Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analyzing speech alone, we can detect cognitive impairment associated with dementia and mental illness. Our assessment can be used in life science research, senior care and clinical settings.

Vocal biomarkers for use in clinical trials

Existing neurological assessments are slow, subjective, and difficult to do remotely. Winterlight’s technology can extract speech-based digital biomarkers from short snippets of speech. The Winterlight Assessment is currently used in a dozen clinical trials to track changes and identify treatment responses. We support life science partners throughout their trials for site onboarding, data collection, speech analysis, and results interpretation.

Work with us

Ratings Quality Assurance

We automate the review of clinical assessment administration and scoring in clinical trials. Using our speech analysis platform we provide fast, reliable auditing and analysis of clinical assessments.


Sign up to access our speech analysis API

We make clinically validated speech-based biomarkers easy to access and use. Our API can be used to receive analyses for speech data you have already collected, or to integrate with your app or device that continuously collects speech in order to receive fast results.

Sign up

Participate in Winterlight studies

We are researching speech patterns in people of all ages to help us build better tools for disease detection and monitoring. This will allow researchers and clinicians to better understand the signs of neurological and psychiatric disease and work towards treatment and cures. We invite you to help us by participating in our research studies.

Tell me more

Developed in partnership with:

What's new

January 11, 2023

Cambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trials

Cambridge Cognition is pleased to announce the acquisition of Winterlight, a leader in monitoring cognitive impairment through free-speech analysis.

Read Read More
October 4, 2022

Winterlight Labs announces data demonstrating the sensitivity of speech-based digital measures in detecting longitudinal change in Alzheimer’s disease in collaboration with Genentech

Winterlight Labs and Genentech have announced new data showing the sensitivity of speech-based digital measures in detecting disease-related longitudinal change in Alzheimer’s disease.

Read Read More
March 29, 2022

Winterlight Labs and Alzheimer Center Amsterdam to decentralize patient assessments in preclinical Alzheimer’s disease research

Winterlight is partnering with Alzheimer Center Amsterdam on a funded study to characterize speech patterns in preclinical Alzheimer's disease and develop tools for remote assessment.

Read Read More
March 15, 2022

Winterlight presents new research relating speech to brain biomarkers for Alzheimer’s disease

In collaboration with Genentech, the research team at Winterlight Labs presented new research at ADPD 2022 showing associations between speech characteristics and cerebral tau accumulation measured by tau PET imaging.

Read Read More

Get in touch

Registered Company Address

Winterlight Labs
100 King Street West
1 First Canadian Place
Suite 6200, P.O. Box 50
Toronto ON M5X 1B8

Send us a message